- Home
- TLSI vs NNY Comparison
TLSI vs NNY Comparison
Compare TLSI & NNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- NNY
- Stock Information
- Founded
- TLSI 2010
- NNY 1987
- Country
- TLSI United States
- NNY United States
- Employees
- TLSI N/A
- NNY N/A
- Industry
- TLSI Medical Specialities
- NNY Investment Managers
- Sector
- TLSI Health Care
- NNY Finance
- Exchange
- TLSI Nasdaq
- NNY Nasdaq
- Market Cap
- TLSI 166.8M
- NNY 161.7M
- IPO Year
- TLSI N/A
- NNY N/A
- Fundamental
- Price
- TLSI $4.70
- NNY $8.56
- Analyst Decision
- TLSI Strong Buy
- NNY
- Analyst Count
- TLSI 2
- NNY 0
- Target Price
- TLSI $14.00
- NNY N/A
- AVG Volume (30 Days)
- TLSI 76.8K
- NNY 50.9K
- Earning Date
- TLSI 11-12-2024
- NNY 01-01-0001
- Dividend Yield
- TLSI N/A
- NNY 4.04%
- EPS Growth
- TLSI N/A
- NNY N/A
- EPS
- TLSI N/A
- NNY N/A
- Revenue
- TLSI $24,736,000.00
- NNY N/A
- Revenue This Year
- TLSI $61.24
- NNY N/A
- Revenue Next Year
- TLSI $47.32
- NNY N/A
- P/E Ratio
- TLSI N/A
- NNY N/A
- Revenue Growth
- TLSI 67.75
- NNY N/A
- 52 Week Low
- TLSI $3.32
- NNY $7.58
- 52 Week High
- TLSI $10.42
- NNY $8.87
- Technical
- Relative Strength Index (RSI)
- TLSI 37.92
- NNY 60.34
- Support Level
- TLSI $4.43
- NNY $8.48
- Resistance Level
- TLSI $5.32
- NNY $8.57
- Average True Range (ATR)
- TLSI 0.35
- NNY 0.06
- MACD
- TLSI -0.04
- NNY -0.00
- Stochastic Oscillator
- TLSI 23.47
- NNY 68.75
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.